HOME >> BIOLOGY >> NEWS
Next-generation AIDS vaccine for healthy individuals being tested for safety, tolerability at UC Davis

(SACRAMENTO, Calif.) A clinical trial testing the safety and tolerability of two investigational AIDS vaccines for healthy individuals is being launched this week at the UC Davis School of Medicine and Medical Center. The study, which is part of a multi-site clinical trial, will enroll up to 126 individuals nationwide. Ten to 20 participants will be recruited into the UC Davis study.

Known as a Phase I clinical trial, the UC Davis study will test the safety and tolerability of genetically engineered vaccines that have been designed to protect the body against HIV infection. Developed by Merck Research Laboratories, the test vaccines include a piece of HIV known as Gag. These next-generation vaccines are based on the use of DNA and a non-infectious particle known as an adenovirus. Because both vaccines are produced through genetic engineering techniques, they do not contain any live virus and cannot cause HIV infection. The HIV-1 gag DNA vaccine includes a man-made copy of one of the genes from HIV, which will make an immune response to the real HIV. The adenovirus serotype 5 HIV-1 vaccine also contains the same man-made copy of the HIV-1 gene but uses a defective, non-infectious respiratory virus (adenovirus) as a backbone. These test vaccines are designed to stimulate the immune system to develop an immune defense against the HIV proteins.

The goal of this study is to evaluate the effect of these vaccines on the immune systems ability to produce T-cell responses and antibodies against HIV-1, said Thomas Evans, professor and chief of the Division of Infectious Diseases at UC Davis School of Medicine and Medical Center and principal investigator of the study. A secondary goal is to assess whether aluminum phosphate, a common additive to vaccine formulas, improves the immune response.

The trial is a double-blind study, with some participants receiving the test vaccines and some participants receiving a placebo, an inactive substance use
'"/>

Contact: Carole Gan
cfgan@ucdavis.edu
916-734-9047
University of California, Davis - Health System
12-Oct-2001


Page: 1 2

Related biology news :

1. Next-generation biomaterials to help body heal itself
2. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
3. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows
4. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
5. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
6. Protective gene may enhance vaccine responses
7. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
8. New glycan arrays discover autoimmunogenic activities of SARS-CoV: concern over monkey vaccine
9. Growing new breed of vaccine-producing plants to fight human diseases worldwide
10. Childrens Hospital Boston receives more than $10 million to help make smallpox vaccine safer
11. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... , ... July 03, 2020 , ... ... to earn outstanding recognition and multiple awards for not only the products and ... portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built by ABM ...
(Date:7/1/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... on building awareness and solutions for glioblastoma—the most common and aggressive adult brain ... Lisa Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s initiatives ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... gene-to-protein and monoclonal antibody development services, today announced that the company has ... services to the pharmaceutical, diagnostics, and research industries. The decision to pursue ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... , ... August 29, 2020 , ... ... Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will provide ... standards and advanced technology. , “This facility will improve the flexibility of ...
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine today revealed that ... FDA compliance consulting has been named on its annual Inc. 5000 list, the ... unique look at the most successful companies within the American economy’s most dynamic ...
(Date:7/31/2020)... Texas (PRWEB) , ... July 29, 2020 , ... ... solutions today announced the launch of its new tagline, “BUILDING FOR LIFE.” The ... biopharmaceutical industry and around the globe, requiring fast track capacity to provide patients ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
Breaking Biology Technology:
Cached News: